Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down39.650 -1.000 (-2.460%)
Research Report

07/04/2021 14:40

{I-bank focus}GS lowers Venus Medtech (02500) to HK$70.77

[ET Net News Agency, 7 April 2021] Goldman Sachs lowered its target price for Venus
Medtech (02500) to HK$70.77 from HK$71.6 and maintained its "buy" rating.
The research house said it maintains the buy rating with a fine-tuned 12-m risk-adjusted
DCF-based TP of HK$70.77 to factor in (1) the updated financials; (2) higher TAVR volume
from aortic regurgitation by 2031E; (3) rollover of DCF model to 2031E (from 2030E). The
DCF assumes (1) a 10% discount rate; (2) a 3% terminal growth rate; and (3) probability of
success (PoS) based on industry average success rates in different stages and adjustments
based on available clinical data - assumptions unchanged. (RC)

Remark: Real time quote last updated: 22/10/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.